Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Etanercept in patients with ankylosing spondylitis: effectiveness and rate of response

Zahraa R. Albagoa, Imad A. Thanoon, Faez Ibraheem Abdulla, Ali A. Younis

. 2022 ; 91 (4) : 266-273. [pub] 20221202

Jazyk angličtina Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc22030431

Introduction: "Ankylosing spondylitis (AS)" is an inflammatory disorder that affects the axial skeleton, peripheral joints, as well as entheses, resulting in significant disability. "Tumor necrosis factor-α (TNF-α)" inhibitors are regarded to be a helpful treatment for patients with active "AS". This study aimed to investigate the effectiveness and response rate of "etanercept" in a group of patients with "ankylosing spondylitis" in Mosul, Iraq.Methods: A prospective, "open-labeled", non-randomized 12 weeks study was undertaken on 43 participants with "ankylosing spondylitis" in the "Rheumatology unit" of "Ibn Sina Teaching Hospital", and the diagnosis was made using the "modified New York criteria". Participants were assessed at the outset of the study, week 4, and week 12 after receiving etanercept 50mg subcutaneously once weekly. The "Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)" was utilized to assess disease activity, while the "Bath Ankylosing Spondylitis Function Index" was utilized to assess functional status (BASFI) at baseline, 4 weeks, and 12 weeks. BASDAI 50 was used to assess the response rate.Results: Mean patients' age was "36.6±8.47" years; men accounted for "90.7 %" of the cases, with the mean disease length being "9.6±5.90" years. A marked decrease in BASFI and BASDAI was found four and twelve weeks after commencing treatment compared to baseline (p=0.000). "BASDAI 50 %" response was fulfilled by 42.5 % of the participants after 4 weeks and by 65%% after 12 weeks of therapy with "etanercept". There was a marked fall in the mean ESR and CRP after four and twelve weeks of "etanercept" therapy.Conclusion: In "AS" patients, once weekly "etanercept" 50 mg given subcutaneously for twelve weeks was an effective therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22030431
003      
CZ-PrNML
005      
20230411134943.0
007      
ta
008      
230209s2022 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.31482/mmsl.2022.001 $2 doi
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Albagoa, Zahraa R. $u Pharmacy Department, Ibn Sina Teaching Hospital, Mosul, Iraq
245    10
$a Etanercept in patients with ankylosing spondylitis: effectiveness and rate of response / $c Zahraa R. Albagoa, Imad A. Thanoon, Faez Ibraheem Abdulla, Ali A. Younis
520    9_
$a Introduction: "Ankylosing spondylitis (AS)" is an inflammatory disorder that affects the axial skeleton, peripheral joints, as well as entheses, resulting in significant disability. "Tumor necrosis factor-α (TNF-α)" inhibitors are regarded to be a helpful treatment for patients with active "AS". This study aimed to investigate the effectiveness and response rate of "etanercept" in a group of patients with "ankylosing spondylitis" in Mosul, Iraq.Methods: A prospective, "open-labeled", non-randomized 12 weeks study was undertaken on 43 participants with "ankylosing spondylitis" in the "Rheumatology unit" of "Ibn Sina Teaching Hospital", and the diagnosis was made using the "modified New York criteria". Participants were assessed at the outset of the study, week 4, and week 12 after receiving etanercept 50mg subcutaneously once weekly. The "Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)" was utilized to assess disease activity, while the "Bath Ankylosing Spondylitis Function Index" was utilized to assess functional status (BASFI) at baseline, 4 weeks, and 12 weeks. BASDAI 50 was used to assess the response rate.Results: Mean patients' age was "36.6±8.47" years; men accounted for "90.7 %" of the cases, with the mean disease length being "9.6±5.90" years. A marked decrease in BASFI and BASDAI was found four and twelve weeks after commencing treatment compared to baseline (p=0.000). "BASDAI 50 %" response was fulfilled by 42.5 % of the participants after 4 weeks and by 65%% after 12 weeks of therapy with "etanercept". There was a marked fall in the mean ESR and CRP after four and twelve weeks of "etanercept" therapy.Conclusion: In "AS" patients, once weekly "etanercept" 50 mg given subcutaneously for twelve weeks was an effective therapy.
650    17
$a etanercept $x aplikace a dávkování $x terapeutické užití $7 D000068800 $2 czmesh
650    17
$a ankylózující spondylitida $x diagnóza $x farmakoterapie $7 D013167 $2 czmesh
650    _7
$a krevní sedimentace $7 D001799 $2 czmesh
650    _7
$a C-reaktivní protein $x analýza $7 D002097 $2 czmesh
650    _7
$a stupeň závažnosti nemoci $7 D012720 $2 czmesh
650    _7
$a inhibitory TNF $x terapeutické užití $7 D000079424 $2 czmesh
650    _7
$a výsledek terapie $7 D016896 $2 czmesh
650    _7
$a prospektivní studie $7 D011446 $2 czmesh
650    _7
$a dospělí $7 D000328 $2 czmesh
650    _7
$a lidé $7 D006801 $2 czmesh
650    _7
$a lidé středního věku $7 D008875 $2 czmesh
700    1_
$a Thanoon, Imad A. $u Department of Pharmacology, College of Medicine, University of Mosul, Mosul, Iraq
700    1_
$a Abdulla, Faez Ibraheem $u Rheumatology Department, Ibn Sina Teaching Hospital, Mosul, Iraq
700    1_
$a Younis, Ali A. $u Department of Medicine, College of Medicine, University of Mosul, Mosul, Iraq
773    0_
$t Vojenské zdravotnické listy $x 0372-7025 $g Roč. 91, č. 4 (2022), s. 266-273 $w MED00011116
856    41
$u https://mmsl.cz/artkey/mms-202204-0001_etanercept-in-patients-with-ankylosing-spondylitis-effectiveness-and-rate-of-response.php $y plný text volně přístupný
910    __
$a ABA008 $b A 3 $c 1073 $y p $z 0
990    __
$a 20230117 $b ABA008
991    __
$a 20230411134940 $b ABA008
999    __
$a ok $b bmc $g 1897195 $s 1181764
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 91 $c 4 $d 266-273 $e 20221202 $i 0372-7025 $m Vojenské zdravotnické listy $x MED00011116
LZP    __
$c NLK193 $d 20230316 $b NLK111 $a Actavia-MED00011116-20230117

Najít záznam

Citační ukazatele

Možnosti archivace